Loading company…
Shenzhen-based Resproly develops respiratory drug delivery technologies, including inhalers, aerosols and nasal sprays.
Founded in 2018 and headquartered in Shenzhen, China, Shenzhen Resproly Biopharmaceutical Co., Ltd., trading as Resproly, was established by Yongqi Chen, a former pharmaceutical expert at UK-based Vectura. Its products include metered dose inhalation aerosols, inhalation powder aerosols, aerosol inhalers and nasal sprays, used in asthma, COPD, diabetes and Parkinson's disease. In December 2025 Guangzhou Industry Investment Holding Group agreed to acquire about 1.77 million shares at CNY 27.67 each, for CNY 49 million, in a PIPE transaction.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in